Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748759 | 1.00 | PARP1 (0.56) | PARP1PRMT5WDR77HTTSMN1; SMN2 | |
| SCHEMBL29655202 | 0.87 | PARP1 (0.58) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19748080 | 0.87 | PARP1 (0.58) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL29655149 | 0.83 | PARP1 (0.59) | PARP1PRMT5WDR77ENPP1LMNA | |
| SCHEMBL19748946 | 0.83 | PARP1 (0.59) | PARP1PRMT5WDR77ENPP1LMNA | |
| SCHEMBL19748474 | 0.83 | PARP1 (0.64) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL29655259 | 0.83 | PARP1 (0.64) | PARP1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL19747669 | 0.82 | PARP1 (0.63) | PARP1HTTCYP3A4CYP2C9TSHR | |
| SCHEMBL29655088 | 0.82 | PARP1 (0.63) | PARP1HTTCYP3A4CYP2C9TSHR | |
| SCHEMBL4572876 | 0.81 | PARP1 (0.72) | PARP1CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-109843874-B | Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer | 加利福尼亚大学董事会 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | PARP1 3/4885PRMT5 1284/4885WDR77 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.